Evidence map›Paper›PMID 34157780›Full record

ArticleCancer2021

Surveillance imaging during first remission in follicular lymphoma does not impact overall survival.

Max L Goldman, Jimmy J Mao, Christopher S Strouse, Wanqi Chen, Manali Rupji, Zhengjia Chen, Matthew J Maurer, Oscar Calzada, Michael Churnetski, Christopher R Flowers and 4 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Article
  4. FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Max L GoldmanDepartment of Medicine, Emory University, Atlanta, Georgia.
Jimmy J MaoDepartment of Medicine, Mayo Clinic, Rochester, Minnesota.
Christopher S StrouseDivision of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa, Iowa City, Iowa.
Wanqi ChenDepartment of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia.ORCID 0000-0002-9991-2274
Manali RupjiDepartment of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia.
Zhengjia ChenDepartment of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia.
Matthew J MaurerDepartment of Biostatistics, Mayo Clinic, Rochester, Minnesota.
Oscar CalzadaDepartment of Hematology and Medical Oncology, Emory University-Winship Cancer Institute, Atlanta, Georgia.
Michael ChurnetskiDepartment of Hematology and Medical Oncology, Emory University-Winship Cancer Institute, Atlanta, Georgia.ORCID 0000-0001-7442-9633
Christopher R FlowersDepartment of Hematology and Medical Oncology, Emory University-Winship Cancer Institute, Atlanta, Georgia.ORCID 0000-0002-9524-3990
James R CerhanDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Brian K LinkDivision of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa, Iowa City, Iowa.
Carrie A ThompsonDivision of Hematology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-4518-2309
Jonathon B CohenDepartment of Hematology and Medical Oncology, Emory University-Winship Cancer Institute, Atlanta, Georgia.ORCID 0000-0002-2723-6481
Emory University · USMayo Clinic · USUniversity of Iowa · USMayo Clinic in Florida · US

Funding

The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI WEINER, GEORGE J. · 2002 to 2021
$45.7M
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (Supplement)U01CA195568 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R, FLOWERS, CHRISTOPHER R · 2015 to 2025
$22.1M
PROGRAM IN HEMOSTASIS AND THROMBOSIS FOR ACADEMICT32HL007344 · NHLBI · UNIVERSITY OF IOWA · PI Anil Kumar Chauhan, Steven R Lentz · 1985 to 2026
$6.5M
American Society of HematologyNCI NIH HHS P50 CA097274NCI NIH HHS U01 CA195568NHLBI NIH HHS T32 HL007344Williams Family Foundation of Georgia
6 · The paper itself

Abstract

backgroundAlthough many patients with follicular lymphoma (FL) undergo routine radiographic surveillance during their first remission, no consensus exists on the modality, duration, frequency, or need for routine imaging studies. The authors retrospectively examined the effect of surveillance imaging on relapse detection and overall survival (OS) in patients with FL.

methodsPatients with newly diagnosed FL who had a response to induction therapy were identified from the Lymphoid Malignancies Enterprise Architecture Database (LEAD) at Emory University and from the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic. Patients were evaluated for both relapse and method of relapse detection (ie, clinical concerns vs radiologic detection through surveillance imaging in an asymptomatic patient).

resultsOf 148 patients in the LEAD cohort, 55 (37%) relapsed, and the majority (n = 35; 64%) of relapses were detected clinically. In the MER cohort, 63 of 177 relapses (54%) were detected clinically. There was no significant difference in OS from the date of diagnosis between the 2 methods of relapse detection in the LEAD (hazard ratio [HR], 0.61; 95% CI, 0.13-2.94; P = .54) and MER (HR, 1.02; 95% CI, 0.47-2.21; P = .96) cohorts. Similarly, there was no significant difference in OS from the date of relapse between the 2 methods of relapse detection in the LEAD (HR, 0.47; 95% CI, 0.10-2.27; P = .35) and MER (HR, 1.02; 95% CI, 0.47-2.21; P = .96) cohorts.

conclusionsThese findings suggest a limited role for routine surveillance imaging in patients with FL who complete front-line therapy. Future studies should evaluate which patients may benefit from a more aggressive surveillance approach and should explore novel methods of relapse detection.

Indexed as

Lymphoma, FollicularDiagnostic ImagingHumansNeoplasm Recurrence, LocalPositron-Emission TomographyRemission InductionRetrospective Studiescomputed tomography (CT)follicular lymphomapositron emission tomography-computed tomography (PET-CT)relapsed follicular lymphomasurveillance

Identifiers

PMID34157780
PMCPMC8800454
OpenAlexW3177100885

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.